Cargando…
Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis
Background: Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide. The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. However, the clinical efficacy and safety of this treatment has not...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797837/ https://www.ncbi.nlm.nih.gov/pubmed/31680944 http://dx.doi.org/10.3389/fphar.2019.01133 |
_version_ | 1783459923155222528 |
---|---|
author | Zhang, Hanlai Xing, Yanwei Chang, Jingling Wang, Liqin An, Na Tian, Chao Yuan, Mengchen Yang, Xinyu Shang, Hongcai Gao, Ying Gao, Yonghong |
author_facet | Zhang, Hanlai Xing, Yanwei Chang, Jingling Wang, Liqin An, Na Tian, Chao Yuan, Mengchen Yang, Xinyu Shang, Hongcai Gao, Ying Gao, Yonghong |
author_sort | Zhang, Hanlai |
collection | PubMed |
description | Background: Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide. The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. However, the clinical efficacy and safety of this treatment has not been statistically and systematically verified by any comprehensive pooled analysis. We therefore performed a meta-analysis to evaluate the efficacy and safety of NSTC in the treatment of IS. Methods: Randomized controlled trials (RCTs) of NSTC in the treatment of IS conducted before September 2018 were retrieved from five databases, according to specific inclusion and exclusion criteria. Two investigators independently reviewed the included studies and extracted relevant data. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook, and analyzed using Review Manager 5.3 software. Results: Thirteen RCTs comprising a total of 1,360 participants were included in this study. NSTC was shown to significantly improve the overall response rate (OR = 3.04, 95% CI [1.76, 5.26], P < 0.00001), and neurological function (NSTC increased Modified Barthel Index (MD = 8.15, 95% CI [3.79, 12.52], P = 0.0005), Functional Independence Measure (MD = 29.61, 95% CI [10.11, 49.10], P = 0.003) and European Stroke Scale scores (MD = 8.51, 95% CI [7.00, 10.01], P = 0.03). In addition, NSTC significantly increased serum adiponectin level (MD = 0.66, 95% CI [0.23, 1.08], P = 0.002). Moreover, NSTC reduced atherosclerotic plaque area (MD = -2.24, 95% CI [-4.02, -0.46], P = 0.01) and intima-media thickness (MD = -0.09, 95% CI [-0.13, -0.05], P < 0.0001). However, there was no significant difference between NSTC treatment and conventional therapy with respect to Fugl-Meyer Assessment score (MD = 10.59, 95% CI [-1.78, 22.96], P = 0.09) or Crouse score (MD = -0.78, 95% CI [-1.79, -0.22], P = 0.13). Conclusions: The results of this meta-analysis showed that NSTC exhibits efficacy in the treatment of cerebral infarction. NSTC can improve the overall response rate and neurological function, increase blood adiponectin, reduce neurological deficits, and decrease atherosclerotic plaque area. |
format | Online Article Text |
id | pubmed-6797837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67978372019-11-01 Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis Zhang, Hanlai Xing, Yanwei Chang, Jingling Wang, Liqin An, Na Tian, Chao Yuan, Mengchen Yang, Xinyu Shang, Hongcai Gao, Ying Gao, Yonghong Front Pharmacol Pharmacology Background: Ischemic stroke (IS) is a leading cause of death and long-term disability worldwide. The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. However, the clinical efficacy and safety of this treatment has not been statistically and systematically verified by any comprehensive pooled analysis. We therefore performed a meta-analysis to evaluate the efficacy and safety of NSTC in the treatment of IS. Methods: Randomized controlled trials (RCTs) of NSTC in the treatment of IS conducted before September 2018 were retrieved from five databases, according to specific inclusion and exclusion criteria. Two investigators independently reviewed the included studies and extracted relevant data. The methodological quality of the included studies was assessed using criteria from the Cochrane Handbook, and analyzed using Review Manager 5.3 software. Results: Thirteen RCTs comprising a total of 1,360 participants were included in this study. NSTC was shown to significantly improve the overall response rate (OR = 3.04, 95% CI [1.76, 5.26], P < 0.00001), and neurological function (NSTC increased Modified Barthel Index (MD = 8.15, 95% CI [3.79, 12.52], P = 0.0005), Functional Independence Measure (MD = 29.61, 95% CI [10.11, 49.10], P = 0.003) and European Stroke Scale scores (MD = 8.51, 95% CI [7.00, 10.01], P = 0.03). In addition, NSTC significantly increased serum adiponectin level (MD = 0.66, 95% CI [0.23, 1.08], P = 0.002). Moreover, NSTC reduced atherosclerotic plaque area (MD = -2.24, 95% CI [-4.02, -0.46], P = 0.01) and intima-media thickness (MD = -0.09, 95% CI [-0.13, -0.05], P < 0.0001). However, there was no significant difference between NSTC treatment and conventional therapy with respect to Fugl-Meyer Assessment score (MD = 10.59, 95% CI [-1.78, 22.96], P = 0.09) or Crouse score (MD = -0.78, 95% CI [-1.79, -0.22], P = 0.13). Conclusions: The results of this meta-analysis showed that NSTC exhibits efficacy in the treatment of cerebral infarction. NSTC can improve the overall response rate and neurological function, increase blood adiponectin, reduce neurological deficits, and decrease atherosclerotic plaque area. Frontiers Media S.A. 2019-10-11 /pmc/articles/PMC6797837/ /pubmed/31680944 http://dx.doi.org/10.3389/fphar.2019.01133 Text en Copyright © 2019 Zhang, Xing, Chang, Wang, An, Tian, Yuan, Yang, Shang, Gao and Gao http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Hanlai Xing, Yanwei Chang, Jingling Wang, Liqin An, Na Tian, Chao Yuan, Mengchen Yang, Xinyu Shang, Hongcai Gao, Ying Gao, Yonghong Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis |
title | Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis |
title_full | Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis |
title_fullStr | Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis |
title_full_unstemmed | Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis |
title_short | Efficacy and Safety of NaoShuanTong Capsule in the Treatment of Ischemic Stroke: A Meta-Analysis |
title_sort | efficacy and safety of naoshuantong capsule in the treatment of ischemic stroke: a meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797837/ https://www.ncbi.nlm.nih.gov/pubmed/31680944 http://dx.doi.org/10.3389/fphar.2019.01133 |
work_keys_str_mv | AT zhanghanlai efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT xingyanwei efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT changjingling efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT wangliqin efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT anna efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT tianchao efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT yuanmengchen efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT yangxinyu efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT shanghongcai efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT gaoying efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis AT gaoyonghong efficacyandsafetyofnaoshuantongcapsuleinthetreatmentofischemicstrokeametaanalysis |